Lexington, Massachusetts, United States and Sydney, Australia – 24 September 2012 – GI
Dynamics, Inc. (ASX: GID) today announced that doctors at St. Vincent’s Clinic and
Macquarie University Hospital (MUH) in Sydney now offer EndoBarrier
® Therapy, a
revolutionary, non-surgical, non-pharmaceutical alternative to help patients take control of
their type 2 diabetes and lose weight at the same time. The St. Vincent’s Clinic is situated
within the greater St. Vincent’s Health Care campus, which is comprised of St. Vincent’s
Public and St. Vincent’s Private Hospitals, both leading centres of innovation and patient care.
Spearheading this treatment is Reginald V. Lord, M.D., F.R.A.C.S., a leading gastrointestinal,
bariatric and general surgeon.
“The level of expertise and innovation offered by Prof. Lord and his team in Sydney is
substantial, and we are thrilled that they have chosen to provide EndoBarrier Therapy,” said
Stuart A. Randle, president and CEO of GI Dynamics. “We are excited about the commercial
progress of EndoBarrier Therapy in Australia, and the addition of St. Vincent’s and MUH is
great news for patients.”
Prof. Lord added, “St. Vincent’s has always been at the forefront of scientific discovery,
medical innovation and patient care, so we are pleased to be able to add this innovative
procedure to our repertoire of obesity and diabetes solutions. We also offer EndoBarrier
Therapy through the new Macquarie University Hospital, which is possibly the most
technologically advanced hospital in Australia. Its location in Sydney’s North West means that
we are able to provide this treatment for patients across the broader Sydney metropolitan
Delivered endoscopically (through the mouth) during a brief, non-surgical procedure, the
EndoBarrier device is a thin, flexible, tube-shaped liner that forms a physical barrier between
food and a portion of the intestinal wall. Once in place, it begins working immediately and has
been shown to lower HbA1c (blood glucose) levels, achieve weight loss of approximately 20 percent and improve other important metabolic functions including cholesterol, blood pressure
and triglycerides within one year. 1,2 EndoBarrier Therapy affects certain gastrointestinal
hormones involved in insulin sensitivity, glucose metabolism and satiety, and these changes
allow for rapid and sustained improvement of type 2 diabetes and weight loss. 3
The Australian Diabetes Council estimates that more than 3.5 million, or one in four,
Australian adults have either diabetes or pre-diabetes; and that type 2 diabetes costs the
country approximately A$3 billion a year. Additionally, more than 17 million Australians are
overweight or obese; and obesity has now overtaken smoking as the leading cause of
premature death and illness in the country.
About EndoBarrier Therapy
EndoBarrier Therapy is a breakthrough treatment for type 2 diabetes and/or obesity that has been clinically
demonstrated to lower HbA1c levels, achieve weight loss of approximately 20 percent, and improve important
metabolic measures including cholesterol, blood pressure and triglycerides.
It has been studied in 13 clinical
trials and has been used in more than 500 patients. The EndoBarrier device is a thin, flexible, tube-shaped liner
that forms a physical barrier between food and a portion of the wall of the intestine. EndoBarrier Therapy affects
certain gastrointestinal hormones involved in insulin sensitivity, glucose metabolism and satiety, and these
changes allow for rapid and sustained improvement of type 2 diabetes and weight loss.
About St. Vincent’s Hospital
St Vincent's Hospital is Australia's second oldest Hospital with an international reputation for its clinical, teaching
and research endeavours and centres of excellence in heart and lung transplantation, bone marrow transplantation,
cardiology, cancer, acquired immune deficiency syndrome/HIV, respiratory medicine, mental health and drug and
St Vincent's Private Hospital is regarded as a pioneer and leading private acute hospital in Australia, providing a
wide range of general and specialist medical and surgical services as well as a young adult mental health
service. The Hospital has particular expertise in areas including cardiac care, cancer, neurosurgery, orthopaedics,
head, neck and reconstructive surgery, urology laser, laparoscopic and robotic surgery. A teaching hospital of UNSW, Notre Dame, University of Tasmania and Australian Catholic University, St Vincent’s Private Hospital is
co-located with both St Vincent’s Clinic and St Vincent’s Public Hospital.
About Macquarie University Hospital
Macquarie University Hospital (MUH) is Australia’s first and only private hospital on a university campus.
Located in Sydney, Australia, MUH is a 183-bed, state-of-the-art facility offering a comprehensive range of
services and specialist areas. With links to the Macquarie University Clinic and the Australian School of
Advanced Medicine, the hospital is part of a large and integrated medical community that features the latest
technology, much of it unavailable anywhere else in the country. Since opening in 2010, it has quickly become a
renowned academic hospital, where doctors are committed to a culture of continuous improvement in patient
care through teaching research. www.muh.org.au
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical
treatments targeting the large and growing global patient populations with type 2 diabetes and obesity. The
company’s flagship product, EndoBarrier®, is a novel, non-surgical device proven to lower blood glucose levels
and promote weight loss in diabetic and obese patients during the implant period. GI Dynamics currently markets
the EndoBarrier in select regions in Europe, South America and Australia, and is planning near-term commercial
expansion into additional markets. The EndoBarrier is not approved for sale in the United States and is considered
investigational. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more
information, please visit www.gidynamics.com.
Moura, GHD, et al, One Year Results of an Endoscopic, Duodenal-Jejunal Exclusion Device for Weight Loss and Control of Type 2
Diabetes. Hospital das Clinicas, University of São Paulo, São Paulo, Brazil. DT&T, February 2012, vol 14, no.2:183-189.
Escalona, A., et al, “Post-explant follow-up after 12 months implantation of an endoscopic duodenal-jejunal bypass liner.”
Department of Digestive Surgery.” Faculty of Medicine Pontificia Universidad Católica de Chile. Annals of Surgery, June 2012 ,Vol
255, Issue 6, p 1080–1085.
C de Jonge, JW Greve, N Bouvy, et al, EndoBarrier Gastrointestinal Liner treatment rapidly improves diabetes parameters paralleled
by increased postprandial GLP-1 and PYY levels in obese type 2 diabetic patients, Department of Surgery, Maastricht University
Medical Centre, presented at IFSO 2011, Hamburg, Germany.
Obesity in Australia, Monash Obesity and Diabetes Institute, 2011.
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and
expectations and on information currently available to management. All statements that address operating performance, events or
developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our
expectations with respect to our ability to commercialize our EndoBarrier® including our estimates of potential revenues, costs,
profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain
reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our
clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities
of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made.
You should not place undue reliance on forward-looking statements because they speak only as of the date when made. GI
Dynamics does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. GI Dynamics may not actually achieve the plans, projections or expectations disclosed in
forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-
looking statements. Forward-looking statements are subject to a number of risks and uncertainties, described in “Risk Factors” in
our Prospectus lodged with the Australian Securities & Investments Commission on 3 August 2011.
Robert Crane, Chief Financial Officer
+1 (781) 357-3250
Susan Heins, Pure Communications Inc.
+ 1 (864) 286-9597
Kim Jacobs, Inteq Limited
+61 2 9231 3322
Rebecca Wilson, Buchan Consulting Group
+61 3 9866 4722